Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 458

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

Open access
Lawn, Stephen D, Mwaba, Peter, Bates, Matthew, Piatek, Amy, Alexander, Heather, Marais, Ben J, Cuevas, Luis E, McHugh, Timothy D, Zijenah, Lynn, Kapata, Nathan, Abubakar, Ibrahim, McNerney, Ruth, Hoelscher, Michael, Memish, Ziad A, Migliori, Giovanni Battista, Kim, Peter, Maeurer, Markus, Schito, Marco, Zumla, Alimuddin·2013·The Lancet Infectious Diseases
DOI 10.1016/s1473-3099(13)70008-2
Open this paper in CoChat — free account

Abstract

Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010. This assay was specifically recommended for use as the initial diagnostic test for suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of countries with a high tuberculosis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated the assay into their national tuberculosis programme guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review the rapidly growing body of scientific literature and discuss the advantages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics pipeline should remain a major priority for funders and researchers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(13)70008-2

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 458

Metadata

Authors
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., Abubakar, I., McNerney, R., Hoelscher, M., Memish, Z. A., Migliori, G. B., Kim, P., Maeurer, M., Schito, M., & Zumla, A.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2013-04
Volume
13
Issue
4
Pages
349-361
ISSN
1473-3099 (ISSN-L)
DOI
10.1016/s1473-3099(13)70008-2
OpenAlex
W2159773654
Cited by
458
References
71
FWCI
45.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. https://app.cochat.ai/papers/10.1016/s1473-3099(13)70008-2
The paper
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., Abubakar, I., McNerney, R., Hoelscher, M., Memish, Z. A., Migliori, G. B., Kim, P., Maeurer, M., Schito, M., & Zumla, A. (2013). Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(13)70008-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.